Claims for Patent: 9,422,564

Summary for Patent: 9,422,564

Title:	Immunostimulatory sequence oligonucleotides and methods of using the same
Abstract:	The invention provides immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides.
Inventor(s):	Dina; Dino (Oakland, CA), Fearon; Karen L. (Lafayette, CA), Marshall; Jason (Oakland, CA)
Assignee:	Dynavax Technologies Corporation (Berkeley, CA)
Application Number:	14/518,933
Patent Claims:	1. An immunomodulatory polynucleotide, consisting of the sequence of SEQ ID NO:55 or SEQ ID NO:172, wherein the polynucleotide comprises at least one phosphorothioate linkage. 2. The immunomodulatory polynucleotide according to claim 1 wherein the polynucleotide consists of the sequence of SEQ ID NO:55. 3. The immunomodulatory polynucleotide according to claim 1 wherein the polynucleotide consists of the sequence of SEQ ID NO: 172. 4. The immunomodulatory polynucleotide according to claim 2 or 3, wherein all nucleotide linkages are phosphorothioate linkages. 5. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the immunomodulatory polynucleotide of claim 4. 6. A method of modulating an immune response in a human comprising: administering the pharmaceutical composition of claim 5 to the human in an amount sufficient to modulate an immune response in the human. 7. A method of increasing interferon-gamma (IFN-.gamma.) in a human, comprising: administering the pharmaceutical composition of claim 5 to the human in an amount sufficient to increase IFN-.gamma. in the human. 8. A method of increasing interferon-alpha (IFN-.alpha.) in a human, comprising: administering the pharmaceutical composition of claim 5 to the human in an amount sufficient to increase IFN-.alpha. in the human. 9. A method of ameliorating a symptom of an infectious disease in a human having an infectious disease, comprising: administering the pharmaceutical composition of claim 5 to the human in an amount sufficient to ameliorate the symptom of the infectious disease. 10. A method of ameliorating a symptom of an IgE-related disorder in a human having an IgE-related disorder, comprising: administering the pharmaceutical composition of claim 5 to the human in an amount sufficient to ameliorate the symptom of the IgE-related disorder. 11. The method of claim 6, wherein the human is receiving a prophylactic vaccine or a therapeutic vaccine. 12. The method of claim 11, wherein the therapeutic vaccine comprises tumor associated antigens and/or tumor cells. 13. The method of claim 6, wherein the method further comprises administration of one or more additional therapeutic agents. 14. The method of claim 13, wherein the one or more additional therapeutic agents comprise an anti-tumor antibody, and the anti-tumor antibody is a monoclonal anti-tumor antibody, fragment, or derivative thereof. 15. The method of claim 13, wherein the one or more additional therapeutic agents comprise an immunotherapeutic agent selected from the group consisting of cytokines, adjuvants and antibodies. 16. The method of claim 13, wherein the one or more additional therapeutic agents is selected from the group consisting of anti-tumor antibodies, chemotherapy regimens and radiation treatments. 17. The method of claim 16, wherein the anti-tumor antibodies comprise rituximab or trastuzumab.

Details for Patent 9,422,564

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2022-12-23
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2022-12-23
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2022-12-23
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2022-12-23
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2022-12-23